Trial reportJournal of human hypertension2010
Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.
Trial report in Journal of human hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Dietary interventions for multiple sclerosis-related outcomes.The Cochrane database of systematic reviews · 2020Pooled it
- Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.EBioMedicine · 2018Trial
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.JAMA neurology · 2014Trial
- Uric Acid and Hypertension: An Update With Recommendations.American journal of hypertension · 2020Review
- Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry.Scientific reports · 2020Article
- Elevated Serum Uric Acid in Benign Convulsions with Mild Gastroenteritis in Children.Journal of clinical neurology (Seoul, Korea) · 2019Article
- Inosine - a Multifunctional Treatment for Complications of Neurologic Injury.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2018Review
- The association between serum uric acid and blood pressure in different age groups in a healthy Chinese cohort.Medicine · 2017Article
- Protection by inosine in a cellular model of Parkinson's disease.Neuroscience · 2014Article
- The protective effects of inosine against chemical hypoxia on cultured rat oligodendrocytes.Cellular and molecular neurobiology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The role of uric acid (UA) in human physiology is subject to controversy. Either it is an important radical scavenger, a mostly neutral, waste metabolic product that may cause gout and kidney stones if elevated, or it is involved in the causation of hypertension, vascular and renal diseases. Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis. An important aspect of the safety profile is whether raising the serum UA levels elevates blood pressure. During the 1-year trial, blood pressure and serum UA levels were monitored in 16 patients. Both parameters were recorded throughout the trial that included 69 visits by patients at baseline and during the placebo phase as well as 138 visits while receiving inosine treatment. We have observed that although the serum UA levels increased significantly during the inosine treatment phase of the trial, from 4.2+/-0.8 to 7.1+/-1.7 mg per 100 ml, blood pressure remained unchanged, averaging 123+/-15/78+/-9. Our findings indicate that raising the serum UA levels to upper normal physiological levels for a period of up to 1-year does not influence blood pressure significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.